Role of microRNA in acute cellular rejection
Anand V. Kulkarni, Shiv K. Sarin, Ashok Choudhury, S.M. Shashthry, Karan Kumar, Lovkesh Anand – 19 January 2017
Reply
Kyoji Ito, Nobuhisa Akamatsu, Norihiro Kokudo – 19 January 2017
Splenectomy is not indicated in living donor liver transplantation
Antonios Athanasiou, Demetrios Moris, Christos Damaskos, Eleftherios Spartalis – 19 January 2017
Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients
Ibrahim Hamad Altraif – 19 January 2017
Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients?
Thomas Karlas, Sebastian Beer, Jonas Babel, Harald Busse, Alexander Schaudinn, Nicolas Linder, Johannes Wiegand, David Petroff – 19 January 2017
Reply
Salvatore Petta, Vincent Way‐Sun Wong, Victor de Ledinghen – 19 January 2017
Potential effect of lamivudine‐induced S gene mutations on liver‐related pathogenesis in hepatitis D virus infection
Anders Boyd, Patrick Miailhes, Karine Lacombe, Fabien Zoulim – 19 January 2017
Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic
Iliana Doycheva, Kymberly D. Watt, Naim Alkhouri – 19 January 2017 – Nonalcoholic fatty liver disease (NAFLD) is a significant health burden in adolescents and young adults (AYAs) which has substantially risen in prevalence over the last decades. The occurrence of NAFLD parallels high rates of obesity and metabolic syndrome in this age group, with unhealthy lifestyle also playing an independent role. Genetic factors, sex, and ethnicity should be considered in a risk stratification model.
Thromboelastography and blood product usage in cirrhosis with severe coagulopathy
Antoni Sabate, Annabel Blasi – 19 January 2017
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
Veeral H. Ajmera, Norah A. Terrault, Stephen A. Harrison – 18 January 2017 – Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied.